A longitudinal big data approach for precision health

Nature Medicine

Volumn 25, Issue 5, 2019, Pages 792-804

  Schüssler Fiorenza Rose, Sophia Miryam ^a,b   Contrepois, Kévin ^a   Moneghetti, Kegan J ^a,c,d   Zhou, Wenyu ^a   Mishra, Tejaswini ^a   Mataraso, Samson ^e,f   Dagan Rosenfeld, Orit ^a   Ganz, Ariel B ^a   Dunn, Jessilyn ^a,c   Hornburg, Daniel ^a   Rego, Shannon ^a   Perelman, Dalia ^a   Ahadi, Sara ^a   Sailani, M Reza ^a   Zhou, Yanjiao ^g,h   Leopold, Shana R ^g   Chen, Jieming ⁱ   Ashland, Melanie ^a   Christle, Jeffrey W ^a,c   Avina, Monika ^a   Limcaoco, Patricia ^a   Ruiz, Camilo ^j   Tan, Marilyn ^a   Butte, Atul J ⁱ   Weinstock, George M ^g   Slavich, George M ^k   Sodergren, Erica ^g   McLaughlin, Tracey L ^a   Haddad, Francois ^a,c   Snyder, Michael P ^a,c   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f University of California   (United States)

^g JACKSON LABORATORY   (United States)

^h UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Stanford University   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTEOME; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; BIG DATA; CARDIOVASCULAR RISK; COHORT ANALYSIS; FEMALE; GENOME; HUMAN; INSULIN RESISTANCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLOME; MICROBIOME; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEOMICS; TRANSCRIPTOMICS; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASE; EXOME; INTESTINE FLORA; MIDDLE AGED; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; BIG DATA; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; EXOME; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; INSULIN RESISTANCE; LONGITUDINAL STUDIES; MALE; METABOLOME; MIDDLE AGED; MODELS, BIOLOGICAL; PRECISION MEDICINE; RISK FACTORS; TRANSCRIPTOME;

EID: 85065589220     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/s41591-019-0414-6     Document Type: Article

References (98)

1. National Research Council (US) Committee on a framework for developing a new taxonomy of disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease (National Academies Press, 2012).
2. Li, X. et al. Digital health: tracking physiomes and activity using wearable biosensors reveals useful health-related information. PLoS Biol. 15, e2001402 (2017).
3. Chen, R. et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148, 1293–1307 (2012).
4. Price, N. D. et al. A wellness study of 108 individuals using personal, dense, dynamic data clouds. Nat. Biotechnol. 35, 747–756 (2017).
5. Perkins, B. A. et al. Precision medicine screening using whole-genome sequencing and advanced imaging to identify disease risk in adults. Proc. Natl Acad. Sci. USA 115, 3686–3691 (2018).
6. Hall, H. et al. Glucotypes reveal new patterns of glucose dysregulation. PLoS Biol. 16, e2005143 (2018).
7. McConnell, M. V. et al. Feasibility of obtaining measures of lifestyle from a smartphone app: the myheart counts cardiovascular health study. JAMA Cardiol 2, 67–76 (2017).
8. Dinneen, S., Gerich, J. & Rizza, R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 327, 707–713 (1992).
9. Varghese, R. T. et al. Mechanisms underlying the pathogenesis of isolated impaired glucose tolerance in humans. J. Clin. Endocrinol. Metab. 101, 4816–4824 (2016).
10. Zhou, W. et al. Complex host-microbial dynamics in prediabetes revealed through longitudinal multi-omics profiling. Nature (in the press).
11. 1000 Genomes Project Consortium. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).
12. Rego, S. et al. High frequency actionable pathogenic exome variants in an average-risk cohort. Cold Spring Harb. Mol. Case Stud. 4, a003178 (2018).
13. Pearson, E. R. et al. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362, 1275–1281 (2003).
14. Cersosimo, E., Solis-Herrera, C., Trautmann, M. E., Malloy, J. & Triplitt, C. L. Assessment of pancreatic β-cell function: review of methods and clinical applications. Curr. Diabetes Rev. 10, 2–42 (2014).
15. Van Cauter, E., Mestrez, F., Sturis, J. & Polonsky, K. S. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance.Diabetes 41, 368–377 (1992).
16. Matsuda, M. & DeFronzo, R. A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–1470 (1999).
17. Godsland, I. F., Jeffs, J. A. R. & Johnston, D. G. Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 47, 1157–1166 (2004).
18. Kanat, M. et al. The relationship between {beta}-cell function and glycated hemoglobin: results from the veterans administration genetic epidemiology study. Diabetes Care 34, 1006–1010 (2011).
19. Iikuni, N., Lam, Q. L. K., Lu, L., Matarese, G. & La Cava, A. Leptin and inflammation. Curr. Immunol. Rev. 4, 70–79 (2008).
20. Hamilton, J. A. GM-CSF in inflammation and autoimmunity. Trends Immunol. 23, 403–408 (2002).
21. Reidy, S. P. & Weber, J. Leptin: an essential regulator of lipid metabolism. Comp. Biochem. Physiol. A 125, 285–298 (2000).
22. Guasch-Ferré, M. et al. Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. Diabetes Care 39, 833–846 (2016).
23. Twig, G. et al. White blood cells count and incidence of type 2 diabetes in young men. Diabetes Care 36, 276–282 (2013).
24. Oliveira, A. G. et al. The role of hepatocyte growth factor (HGF) in insulin resistance and diabetes. Front. Endocrinol. 9, 503 (2018).
25. Mothe-Satney, I. et al. Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice. Diabetes 61, 2311–2319 (2012).
26. Tsamardinos, I., Brown, L. E. & Aliferis, C. F. The max-min hill-climbing Bayesian network structure learning algorithm. Mach. Learn. 65, 31–78 (2006).
27. Lagani, V., Athineou, G., Farcomeni, A., Tsagris, M. & Tsamardinos, I. Feature selection with the R Package MXM: discovering statistically equivalent feature subsets. J. Stat. Softw. 80, 1–25 (2017).
28. McLaughlin, T. et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann. Intern. Med. 139, 802–809 (2003).
29. Nowak, C. et al. Protein biomarkers for insulin resistance and type 2 diabetes risk in two large community cohorts. Diabetes 65, 276–284 (2016).
30. Apostolopoulou, M. et al. Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis. Diabetes Care 41, 1235–1243 (2018).
31. Gomez-Arango, L. F. et al. Connections between the gut microbiome and metabolic hormones in early pregnancy in overweight and obese women. Diabetes 65, 2214–2223 (2016).
32. Kwo, P. Y., Cohen, S. M. & Lim, J. K. ACG clinical guideline: evaluation of abnormal liver chemistries. Am. J. Gastroenterol. 112, 18–35 (2017).
33. Hu, F. B. et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25, 1129–1134 (2002).
34. Goff, D. C. Jr et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129, S49–S73 (2014).
35. Kuznetsova, T. et al. Additive prognostic value of left ventricular systolic dysfunction in a population-based cohort. Circ. Cardiovasc. Imag. 9, e004661 (2016).
36. Wang, T. J. et al. Carotid intima-media thickness is associated with premature parental coronary heart disease: the Framingham Heart Study. Circulation 108, 572–576 (2003).
37. Mitchell, G. F. et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 121, 505–511 (2010).
38. Moneghetti, K. J. et al. Applying current normative data to prognosis in heart failure: the fitness registry and the importance of exercise national database (FRIEND). Int. J. Cardiol. 263, 75–79 (2018).
39. Hall, K. T. et al. Polymorphisms in catechol-O-methyltransferase modify treatment effects of aspirin on risk of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 34, 2160–2167 (2014).
40. Malik, R. et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes.Nat. Genet. 50, 524–537 (2018).
41. Cross, D. S. et al. Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts. Curr. Med. Res. Opin. 28, 1819–1830 (2012).
42. Ma, H., Calderon, T. M., Fallon, J. T. & Berman, J. W. Hepatocyte growth factor is a survival factor for endothelial cells and is expressed in human atherosclerotic plaques. Atherosclerosis 164, 79–87 (2002).
43. Bell, E. J. et al. Hepatocyte growth factor is positively associated with risk of stroke: the MESA (Multi-Ethnic Study of Atherosclerosis). Stroke 47, 2689–2694 (2016).
44. Chen, X. & Devaraj, S. Monocytes from metabolic syndrome subjects exhibit a proinflammatory M1 phenotype. Metab. Syndr. Relat. Disord. 12, 362–366 (2014).
45. Elkind, M. S. et al. Interleukin-2 levels are associated with carotid artery intima-media thickness. Atherosclerosis 180, 181–187 (2005).
46. Porez, G., Prawitt, J., Gross, B. & Staels, B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J. Lipid Res. 53, 1723–1737 (2012).
47. Berry, C. E. & Hare, J. M. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J. Physiol. 555, 589–606 (2004).
48. Sane, D. C., Kontos, J. L. & Greenberg, C. S. Roles of transglutaminases in cardiac and vascular diseases. Front. Biosci. 12, 2530–2545 (2007).
49. Wollert, K. C., Kempf, T. & Wallentin, L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin. Chem. 63, 140–151 (2017).
50. Klok, M. D., Jakobsdottir, S. & Drent, M. L. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes. Rev. 8, 21–34 (2007).
51. Charbonneau, B. et al. Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. Cytokine 60, 882–889 (2012).
52. Przewoznik, M. et al. Recruitment of natural killer cells in advanced stages of endogenously arising B-cell lymphoma: implications for therapeutic cell transfer. J. Immunother. 35, 217–222 (2012).
53. Haabeth, O. A. W. et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat. Commun. 2, 240 (2011).
54. Ding, Q. et al. CXCL9: evidence and contradictions for its role in tumor progression. Cancer Med. 5, 3246–3259 (2016).
55. Rolny, C. et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19, 31–44 (2011).
56. Johnson, L. D. S., Goubran, H. A. & Kotb, R. R. Histidine rich glycoprotein and cancer: a multi-faceted relationship. Anticancer Res. 34, 593–603 (2014).
57. Go, R. S., Gundrum, J. D. & Neuner, J. M. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. Clin. Lymphoma Myeloma Leuk. 15, 177–186.e4 (2015).
58. Turesson, I. et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood 123, 338–345 (2014).
59. Alqvist E. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 6, P361–P369 (2018).
60. Cauwenberghs, N. et al. Relation of insulin resistance to longitudinal changes in left ventricular structure and function in a general population. J. Am. Heart Assoc. 7, e008315 (2018).
61. Piening, B. D. et al. Integrative personal omics profiles during periods of weight gain and loss. Cell Syst. 6, 157–170.e8 (2018).
62. Whirl-Carrillo, M. et al. Pharmacogenomics knowledge for personalized medicine. Clinical Pharmacol. Ther. 92, 414–417 (2012).
63. Li, J. et al. Decoding the genomics of abdominal aortic aneurysm. Cell 174, 1361–1372.e10 (2018).
64. Douglas, P. S. et al. The future of cardiac imaging: report of a think tank convened by the american college of cardiology. JACC Cardiovasc. Imag. 9, 1211–1223 (2016).
65. Buhr, S. Apple’s Watch isn’t the first with an EKG reader but it will matter to more consumers. TechCrunch https://techcrunch.com/2018/09/12/apples-watch-isnt-the-first-with-an-ekg-reader-but-it-will-matter-to-more-consumers/ (2018).
66. Omer, W., Naveed, A. K., Khan, O. J. & Khan, D. A. Role of cytokine gene score in risk prediction of premature coronary artery disease. Genet. Test. Mol. Biomarkers 20, 685–691 (2016).
67. Integrated Molecular Pathway Level Analysis (accessed 27 December 2018); http://impala.molgen.mpg.de/
68. Szklarczyk, D. et al. STRINGv10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447–D452 (2015).
69. The Integrative Human Microbiome Project. Dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe 16, 276–289 (2014).
70. Cohen, S. & Williamson, G. in The Social Psychology of Health (eds Spacapan, S. and Oskamp, S.) 31–67 (Sage Publications, 1988).
71. Slavich, G. M. & Shields, G. S. Assessing lifetime stress exposure using the Stress and Adversity Inventory for adults (Adult STRAIN): an overview and initial validation. Psychosom. Med. 80, 17–27 (2018).
72. Lee, P. H., Macfarlane, D. J., Lam, T. H. & Stewart, S. M. Validity of the international physical activity questionnaire short form (IPAQ-SF): a systematic review. Int. J. Behav. Nutr. Phys. Act. 8, 115 (2011).
73. Pei, D., Jones, C. N. O., Bhargava, R., Chen, Y.-D. I. & Reaven, G. M. Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test. Diabetologia 37, 843–845 (1994).
74. Lam, H. Y. K. et al. Detecting and annotating genetic variations using the HugeSeq pipeline. Nat. Biotechnol. 30, 226–229 (2012).
75. Kalia, S. S. et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SFv2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet. Med. 19, 249–255 (2017).
76. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105–1111 (2009).
77. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 1–21 (2014).
78. Luminex Multiplex Analysis (Stanford Human Immune Monitoring Core, 2018); http://iti.stanford.edu/content/dam/sm/iti/documents/himc/protocols/LuminexMultiplexAnalysisprotocol030213.doc
79. Contrepois, K., Jiang, L. & Snyder, M. Optimized analytical procedures for the untargeted metabolomic profiling of human urine and plasma by combining hydrophilic interaction (HILIC) and reverse-phase liquid chromatography (RPLC)-mass spectrometry. Mol. Cell. Proteomics 14, 1684–1695 (2015).
80. Contrepois, K. et al. Cross-platform comparison of untargeted and targeted lipidomics approaches on aging mouse plasma. Sci. Rep. 8, 17747 (2018).
81. Lang, R. M. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 28, 1–39.e14 (2015).
82. Wilson, P. W. F. et al. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837–1847 (1998).
83. Smith, D. A. In adults without CVD, the MESA score, including coronary artery calcium, predicted 10-y risk for CHD events. Ann. Intern. Med. 164, JC35 (2016).
84. McClelland, R. L. et al. 10-Year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the mesa (multi-ethnic study of atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) study and the DHS (Dallas Heart Study). J. Am. Coll. Cardiol. 66, 1643–1653 (2015).
85. Lee, K. K., Cipriano, L. E., Owens, D. K., Go, A. S. & Hlatky, M. A. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. Circulation 122, 1478–1487 (2010).
86. Myers, J., Bader, D., Madhavan, R. & Froelicher, V. Validation of a specific activity questionnaire to estimate exercise tolerance in patients referred for exercise testing. Am. Heart J. 142, 1041–1046 (2001).
87. Arena, R., Myers, J., Aslam, S. S., Varughese, E. B. & Peberdy, M. A. Technical considerations related to the minute ventilation/carbon dioxide output slope in patients with heart failure. Chest 124, 720–727 (2003).
88. Kaminsky, L. A., Imboden, M. T., Arena, R. & Myers, J. Reference standards for cardiorespiratory fitness measured with cardiopulmonary exercise testing using cycle ergometry: data from the fitness registry and the importance of exercise national database (FRIEND) Registry. Mayo Clin. Proc. 92, 228–233 (2017).
89. Hovorka, R., Soons, P. A. & Young, M. A. ISEC: a program to calculate insulin secretion. Comput. Methods Programs Biomed. 50, 253–264 (1996).
90. Kamburov, A., Cavill, R., Ebbels, T. M. D., Herwig, R. & Keun, H. C. Integrated pathway-level analysis of transcriptomics and metabolomics data with IMPaLA. Bioinformatics 27, 2917–2918 (2011).
91. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
92. Fruchterman, T. M. J. & Reingold, E. M. Graph drawing by force-directed placement. Softw. Pract. Exp. 21, 1129–1164 (1991).
93. Montagna, P. A. Using SAS to manage biological species data and calculate diversity indices. in 2014 SCSUG Educational Forum (South Central SAS Users Group, 2014).
94. Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335–336 (2010).
95. Callahan, B. J. et al. DADA2: High-resolution sample inference from Illumina amplicon data. Nat. Methods 13, 581–583 (2016).
96. Bokulich, N. A. et al. Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2’s q2-feature-classifier plugin. Microbiome 6, 90 (2018).
97. Callahan, B. J., McMurdie, P. J. & Holmes, S. P. Exact sequence variants should replace operational taxonomic units in marker-gene data analysis. ISME J. 11, 2639 (2017).
98. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).